Associate Professor, Department of Otolaryngology - Head and Neck Surgery

Jas C LangTzagournis Medical Research Facility
420 W. 12th Ave.
Columbus, OH 43210

614-685-4324
James.Lang@osumc.edu


Research interests: Investigation of the genetic changes associated with the development of squamous cell carcinoma of the head and neck (SCCHN). We are presently investigating the genetic changes responsible for the altered cellular metabolism found in SCCHN. To aid these studies we are isolating cancer cells from tumor tissue and blood obtained from head and neck cancer patients. Cancer cells are purified from blood and tissue utilizing a novel magnetic cell separation system developed by our collaborators in the Chemical Engineering Department at The Ohio State University. The tumor cells isolated in this way can then be used as prognostic indicators to follow the clinical course of the disease in patients and to investigate the molecular changes associated with the development of squamous cell carcinoma of the head and neck.

Education
PhD: University of Glasgow, 1984

View CV

Funded Research

Funded research - principal investigator:

American Cancer Society, $12,000, November 1, 1990 to October 31, 1991, "Analysis of regulatory domains with exon 1 of human c-myc." PI: Jas C. Lang. Dr. Lang alone formulated the research plan and wrote grant proposal. Intellectual contribution 100%

American Cancer Society, Ohio Division, $15,000, November 1, 1990 to October 31, 1991, "Construction and characterization of a transforming DNA isolated from CML (and its normal counterpart)." PI: Jas C. Lang. Dr. Lang alone formulated the research plan and wrote grant proposal. Intellectual contribution 100%

Ohio Board of Regent's Research Challenge Program, $14,300, April 1, 1991 to March 30, 1992, "Analysis of regulatory domains within exon 1 of human c-myc and their role in Burkitts Lymphoma." PI: Jas C. Lang. Dr. Lang alone formulated the research plan and wrote grant proposal. Intellectual contribution 100%

Leukemia Research Foundation, Inc., $34,900, July 1, 1992 to September 30, 1993, "Characterization of a novel transforming gene from CML." PI: Jas C Lang. Dr. Lang alone formulated the research plan and wrote grant proposal. Intellectual contribution 100%

National Institutes of Health/National Cancer Institute First Award R29#CA 63134, $508,191, May 1, 1994 to April 30, 2001, "Regulation and oncogenic function of growth factor FGF4." PI: Jas C Lang. Dr. Lang alone formulated the research plan and wrote grant proposal. Intellectual contribution 100%

CCC SPORE Program Project Developmental Grant Funds, $18,000, February 1, 2001 to Jan 30, 2002. Role of DESC1 in development of squamous cell carcinoma of the head and neck." PI: Jas C Lang. Intellectual contribution 100%

National Institutes of Health/National Institute for Dental and Craniofacial Research PO1 # DE12704, July 1, 1998 to June 30, 2005, PI: Gary D Stoner. “Molecular events in progression of oral cancer.” Role on project: Project Leader Project #2 “Role of G1 Phase Regulatory Genes and Identification of Differentially Expressed Novel Genes in Development of Oral Cancer” Direct costs Project #2 $501,144. Dr. Lang formulated research plan and wrote grant proposal for Project #2. Intellectual contribution 100%

Pending: 

NIH, National Cancer Institute (NCI) Clinical Assay Development Program (CADP) RFP 14-004. The CADP provides services to support development of robust clinical assays for prognosis and prediction in cancer. This submission is to apply for status as a collaborating laboratory for the CADP for HNSCC.

Funded research - co-principal investigator:

Cancer Center Support Grant, Ohio State University, $90,000, July 1, 1991 to June 30, 1993, Principal Investigators: Deborah Parris, Pravin Kaumaya and Jas C. Lang. "Development of random peptides libraries." Role on project: Co-PI. Dr. Lang contributed to research plan and grant preparation. Intellectual contribution 25%

Ohio State University Interdisciplinary Seed Grant Proposal, $60,000, July 1, 1994 to June 30, 1996, PIs: Roy A Tassava, Ing-Ming Chiu and Jas C Lang. “Growth control in salamander limb regeneration: roles of fibroblast growth factors 1 and 4.” Role on project: Co-PI. Dr. Lang
contributed to research plan and grant preparation. Intellectual contribution 25%.

American Cancer Society, Ohio Division, $16,475, August 25, 1995 to August 24, 1996, Principal Investigators: Gregory J Lavalle and Jas C Lang. “Detection of circulating melanoma cells as a marker of metastatic disease.” Role on project: Co-PI. Dr. Lang contributed to research plan and grant preparation. Intellectual contribution 20%

National Cancer Institute Oncology Training Grant, #2T32CA09338, $902,360, July 1, 1994 to June 30, 1999, PI Stanley P Balcerzak. Role on project: Training faculty. Dr. Lang reviewed grant application before submission. Intellectual contribution 5%

National Cancer Institute Program Project Developmental Grant, $130,000, July 1, 1997 to June 30, 1999, Principal Investigator Gary D Stoner. “Molecular events in progression of oral cancer.” Role on project:  Project Leader on Project #2, entitled “Role of G1 Phase Regulatory Genes and Identification of Differentially Expressed Novel Genes in Development of Oral Cancer.” Dr. Lang formulated research plan and wrote grant proposal for Project #2. Intellectual contribution 100%

NIH, National Cancer Institute U01 CA076576, 1998-2008, Phase I Trials of Anti-Cancer Agents. PI: Grever. Role on project: Co-investigator. Trial of OSI774 in head and neck cancer.

NIH, NIDCR RO1 DE013123, 2000-20012 Genomic Scanning in Oral Cancer PI, Plass. Role on project: consultant

NIH, National Cancer Institute, RO1 CA62349. 02/18/04-01/31/08, Principal Investigator Maciej Zborowski “Continuous Cell Sorting by Magnetophoresis,” Role on project: co-investigator.

Peer Reviewed Journal Articles

Yang L, Lang JC, Balasubraman P, Jatana K, Schuller D, Agarwal A, Zborowski M,  Chalmers JJ. Optimization of an enrichment process for circulating tumor cells from the blood of head and neck cancer patients through depletion of normal cells. Biotechnology and Bioengineering, 102:521-534, 2009
   
Richards KL, Zhang B,  Baggerly KA, Colella S, Lang JC, Schuller DE, and Krahe R. Genome-wide hypomethylation in HNSCC is more pronounced in HPV-negative tumors and is associated with genomic instability. PLoS One. 4(3):e4941. Epub 2009, Mar 19
   
Balasubramanian P, Yang L, Lang JC, Jatana KR, Schuller D, Agrawal A, Zborowski M, Chalmers JJ. Confocal images of circulating tumor cells obtained using a methodology and technology that removes normal cells. Mol Pharm. 6:1402-1408, 2009
   
Kraut, EH, Rhoades C, Chan KK, Lang J, Young DC, Aimiumu J, Agrawal A, Chen P, Cheng H, Zhang Y, Dancey J,  Grever MR. Phase I and pharmacokinetic study of OSI-774 ( Erlotinib) in combination with docetaxel in squamous cell carcinoma of the head and neck (SCCHN). Cancer Chemother Pharmacol. May 19, 2010 [Epub ahead of print]
   
Jatana KR, Balasubramanian P, Lang JC, Yang L, Jatana CA, White E, Agrawal A, Ozer E, Schuller DE, Teknos T, Chalmers JJ. Significance of circulating tumor cells in patients with squamous cell carcinoma of the head and neck. Arch Otolaryngol. Head and Neck Surg. 136:1274-1279, 2010

Jatana KR, Lang JC, Chalmers JJ. Identification of circulating tumor cells: a prognostic marker in squamous cell carcinoma of the head and neck? Future Oncology. 7:481-484, 2011

Li J, Knobloch TJ, Kresty LA, Zhang Z, Lang JC, Schuller DE, Weghorst CM. Gankyrin, a biomarker for epithelial carcinogenesis, is overexpressed in human oral cancer. Anticancer Res. 31:2683-2692,2011

Datta J, Smith A, Lang JC, Islam M, Dutt D, Teknos TN, Quintin Pan Q. miRNA-107 functions as a candidate tumor suppressor gene in head and neck squamous cell carcinoma by down-regulation of protein kinase Cε. Oncogene. 31:4045-4053, 2012

Kumar B, Yadav A, Lang JC, Cipolla M, Schmitt AC, Arradaza N, Teknos TN, Kumar P. YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels.Mol Cancer Ther. 9:1988-1998, 2012

Kumar B, Yadav A, Lang J, Teknos TN, Kumar P. Dysregulation of MicroRNA-34a Expression in Head and Neck Squamous Cell Carcinoma Promotes Tumor Growth and Tumor Angiogenesis.PLoS One. 2012;7(5):e37601. Epub 2012 May 22

Balasubramanian P, Lang JC , Jatana KR, Miller B, Ozer E, Old M, Schuller DE, Agrawal A, Teknos TN, Summers TA, Lustberg MB, Zborowski M, Chalmers JJ. Multiparameter analysis, including EMT markers, on negatively enriched blood samples from patients with squamous cell carcinoma of the head and neck. PLoS ONE, 2012, 7(7):e42048 Epub 2012 May 26.

Zhang M, Taylor CE, Piao L, Datta J, Bruno PA, Bhave S, Su T, Lang JC, Teknos TN, Anna K. Mapp AK, Pan Q. Genetic and chemical targeting of epithelial-restricted with serine box reduces epidermal growth factor receptor and potentiates the efficacy of afatinib. Mol Cancer Ther. 12:1515-1525, 2013

Islam M, Datta J, Lang J, Teknos TN. Down regulation of RhoC by MicroRNA-138 results in de-activation of FAK, Src and Erk1/2 signaling pathway in head and neck squamous cell carcinoma. Oral Oncol. 50:448-456, 2014 

Kris R. Jatana KR, Balabasubraman P, Lang JC, Teknos TN, Chalmers JJ. Effect of surgical intervention on circulating tumor cells in patients with squamous cell carcinoma of the head and neck using a negative enrichment technology. Manuscript submitted

Li R, Faden DL, Langelier C, Jiao Y, Wang Y, Wilkerson M, Sekhar PC, Old M, Lang JC, Loyo M, Ahn J, Tan M, Gooi Z, Chan J, Wood LD, Hruban RH, Bishop J, Westra WH, Chung CH, Califano J, Gourin CG, Fakhry C, Bettegowda C, Myerson M, Papadopoulos N, Kinzler KW, Vogelstein B, Koch WM, DeRisi JL, Agrawal N. Clinical, Genomic and Metagenomic Characterization of Oral Tongue Squamous Cell Carcinoma in Patients Who Do Not Smoke. Manuscript submitted

Kumar B, YadavA, Lang JC, Teknos TN, Kumar P, Suberoylanilide hydroxamic acid (SAHA) reverses chemoresistance in head and neck cancer cells by targeting cancer stem cells. Manuscript submitted

Lee Y, Jatana KR, Hurtuk A, Teknos T, Ozer E, Old M, Agrawal A, McLaughlin J, Fraser SR, Wyborny T, Lang JC. Overexpression and mutation of facilitative glucose transporter Glut1 in squamous cell carcinoma of the head and neck. Manuscript in preparation.
   
Jatana KR, Malone JP, Agrawal A, Baran JL, Schuller DE, Lang JC. Quantitative mRNA and mutational analysis of p16 in primary and recurrent squamous cell carcinomas of the head and neck. Manuscript in preparation

Teaching and Mentoring

Undergraduate, graduate and professional courses
Dr. Lang teaches on the following courses:

• Molecular Genetics 733 Human Genetics
• Pathology 640 Fundamentals of Oncology
• BMS 583 Cancer Research – Towards Personalized Medicine

Graduate and thesis mentoring
PhD Candidacy Exam Priya Balasubramanian March 2009 (co-mentor)
PhD Thesis Defense Faculty Representative Christianna Thomas-Hurford July 2010
PhD Thesis Defense Priya Balasubramanian October 2010 (co-mentor)
PhD Candidacy Exam Brian Han September 2011 (thesis committee member)
PhD Thesis Defense Andrew Holpuch March 2014 (thesis committee member)
Priya Balasubramanian: Second Prize Hayes Graduate Research Forum

Continuing education instruction
Dr. Lang was Module Leader for graduate teaching module 702.04 entitled “Cancer Biology” as part of the core curriculum of the Integrated Biomedical Science Graduate Program (IBGP). Dr. Lang was responsible for conceptualization, preparation, coordination and teaching of this 25-hour course module. This module was offered annually in Spring Quarter through 2012 and covered both clinical and molecular aspects of specific cancers and the regulation of cell growth and cell death in normal, diseased and neoplastic cells.  

Dr. Lang was also responsible for recruitment of faculty to aid teaching of this module. In 2013 disease-specific modules were removed from the IBGP core curriculum and this course was closed.

Laboratory instruction

Research assistant/associate: pre-med training:

Tessa Wyborny, 2006 - 2008. Graduate research assistant. Tessa investigated the mutational status of the gap junction protein connexin 43 in head and neck cancer and the HPV status of SCCHN tumor specimens. Present status: medical student Creighton University Medical School, Nebraska.

Erin Wolf, summer 2008 and 2009. Student research assistant. Erin is performing an analysis of the HPV frequency in specimens of SCCHN obtained from patients presenting with carcinoma of unknown primary and investigating the process of abnormal glycolysis in SCCHN.

Graham Neil, summer 2009. Student research assistant. Graham investigated the mechanisms for detection of HPV in both DNA and RNA from SCCHN patients with oropharyngeal tumors.

Christopher Malone 2009 - 2010. Pre-med undergraduate student volunteer. Chris performed RT-PCR experiments to investigate the cytokeratin profile of head and neck cancers.

Simon Fraser winter 2010 – summer 2011. Pre-Med graduate student volunteer. Simon investigated the gene expression profile of tumor specimens obtained from patients enrolled on an Intensification Regimen Protocol for treatment of head and neck cancer. 

College of Medicine, Department of Otolaryngology Residents: 


Kris Jatana, MD 2004 - 2009. Studying the mutational status of the tumor suppressor gene p16 in recurrent and non-recurrent cancers of the head and neck. Dr. Jatana is also involved in a joint collaborative project with the Department of Chemical Engineering to isolate circulating cancer cells from the peripheral blood of head and neck cancer patients. Winner of the annual Saunders Lectureship Award for his research presentations in years 2007, 2008 and 2009.

Agnes Oplatek, MD 2009 – 2011. Agnes collaborated on our studies of circulating tumor cells in head and neck cancer and in the establishment of tumor cell cultures from HNSCC specimens.